Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine

Clemens Warnke, Heinz Wiendl, Hans Peter Hartung, Olaf Stüve, Bernd C. Kieseier

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.

Original languageEnglish (US)
Pages (from-to)117-126
Number of pages10
JournalDrug Design, Development and Therapy
Volume4
StatePublished - 2010

Fingerprint

Cladribine
Multiple Sclerosis
Pharmaceutical Preparations
Relapsing-Remitting Multiple Sclerosis
Chronic Disease

Keywords

  • Immunosuppressant
  • Oral drugs
  • Risk-benefit
  • Safety

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine. / Warnke, Clemens; Wiendl, Heinz; Hartung, Hans Peter; Stüve, Olaf; Kieseier, Bernd C.

In: Drug Design, Development and Therapy, Vol. 4, 2010, p. 117-126.

Research output: Contribution to journalArticle

Warnke, Clemens ; Wiendl, Heinz ; Hartung, Hans Peter ; Stüve, Olaf ; Kieseier, Bernd C. / Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine. In: Drug Design, Development and Therapy. 2010 ; Vol. 4. pp. 117-126.
@article{29fc3fb68e9b4a0d8933c58ad00f08db,
title = "Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine",
abstract = "Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.",
keywords = "Immunosuppressant, Oral drugs, Risk-benefit, Safety",
author = "Clemens Warnke and Heinz Wiendl and Hartung, {Hans Peter} and Olaf St{\"u}ve and Kieseier, {Bernd C.}",
year = "2010",
language = "English (US)",
volume = "4",
pages = "117--126",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine

AU - Warnke, Clemens

AU - Wiendl, Heinz

AU - Hartung, Hans Peter

AU - Stüve, Olaf

AU - Kieseier, Bernd C.

PY - 2010

Y1 - 2010

N2 - Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.

AB - Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future.

KW - Immunosuppressant

KW - Oral drugs

KW - Risk-benefit

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=79952033985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952033985&partnerID=8YFLogxK

M3 - Article

C2 - 20689698

AN - SCOPUS:79952033985

VL - 4

SP - 117

EP - 126

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -